Announcement of the Implementation Status of the Remediation Plan for Excessive Intercompany Loans by Subsidiary
AI Summary (NQ-processed)
Mei-Shih announced the completion of a remediation plan regarding excessive fund lending by its subsidiary, Alvogen Pharma US Inc. The company has strengthened internal controls and governance procedures in response to regulatory requirements.
AI Analysis
Frequently Asked Questions
Q: Why did Mei-Shih's subsidiary face a fund lending issue?
A: The subsidiary exceeded lending limits, prompting regulatory correction orders from Taiwan's FSC.
Q: What does the remediation plan include?
A: It includes procedure establishment, policy revisions, and reporting to audit and board committees.
Q: What impact does this have on shareholders?
A: No major financial impact, but it raises governance transparency concerns.
Q: When must the remediation be completed?
A: By June 30, 115, as directed by the Financial Supervisory Commission.
Q: What is the ownership status of Alvogen Pharma US Inc.?
A: It is a 100%-owned subsidiary of Mei-Shih and consolidated in its financials.